Meta stock closes up on Manus AI agent deal — what investors are watching next

Meta stock closes up on Manus AI agent deal — what investors are watching next

NEW YORK, December 30, 2025, 16:04 ET — After-hours Meta Platforms, Inc. shares closed higher on Tuesday after the Facebook owner said it would acquire Chinese-founded artificial intelligence startup Manus, a move that put fresh focus on the company’s push into advanced AI features. Meta ended the regular session at $666.49, up 1.2%. Yahoo Finance+1 The purchase matters because “AI agents” — software designed to carry out multi-step tasks with limited instructions — are emerging as the next battleground for consumer and business AI, and investors are looking for clear product paths rather than research demos. Manus markets itself as
Tesla stock today: TSLA slips after company posts delivery-consensus table ahead of Friday numbers

Tesla stock today: TSLA slips after company posts delivery-consensus table ahead of Friday numbers

NEW YORK, December 30, 2025, 16:07 ET — After-hours Tesla shares fell about 0.8% on Tuesday to $455.75 after the electric-vehicle maker published a company-compiled analyst consensus that points to a weaker fourth-quarter delivery count. The timing matters: Tesla is expected to report its official fourth-quarter and full-year production and delivery tally on Friday (Jan. 2), and analysts expect a year-over-year decline after U.S. tax credits expired in September. Tesla’s cheaper “Standard” versions of the Model Y and Model 3, launched in October, have not erased worries about demand and competition. Reuters Deliveries are Wall Street’s cleanest read on near-term
Dutch Bros stock slides 3% as coffee-cost worries return — what investors are watching

Dutch Bros stock slides 3% as coffee-cost worries return — what investors are watching

NEW YORK, December 30, 2025, 15:43 ET — Regular session Dutch Bros Inc. (BROS) shares fell about 3.4% to $62.30 in afternoon trading on Tuesday. The stock has traded between $62.30 and $64.55 after closing at $64.48 on Monday. The move matters for investors because Dutch Bros has been priced as a fast grower, leaving little room for cost surprises as 2025 trading winds down and liquidity thins. A note published earlier on Nasdaq.com said Dutch Bros ended the third quarter with about $706 million of liquidity — cash plus unused borrowing capacity — which can help cushion volatility in
Oklo stock slips in afternoon trade as insider trust transfers hit filings, eyes on nuclear licensing

Oklo stock slips in afternoon trade as insider trust transfers hit filings, eyes on nuclear licensing

NEW YORK, December 30, 2025, 3:38 PM ET — Regular session Oklo Inc (OKLO) shares fell 2.3% to $72.42 in afternoon trading on Tuesday, after earlier swinging between $74.73 and $71.90. About 5.7 million shares had changed hands. The pullback matters because Oklo is still in the “story stock” phase: it is developing advanced nuclear reactors and investors largely price the shares on regulatory progress, funding runway and customer demand rather than current revenue. That mix can amplify moves around filings and policy headlines. A Form 4 filing signed late Monday showed Oklo co-founder and Chief Operating Officer Caroline Cochran
MongoDB stock today: MDB slips as “MongoBleed” vulnerability and patch push stay in focus

MongoDB stock today: MDB slips as “MongoBleed” vulnerability and patch push stay in focus

NEW YORK, December 30, 2025, 15:47 ET — Regular session. MongoDB, Inc. shares were down about 0.3% at $422.06 in late-afternoon trade on Tuesday, after swinging between $421.85 and $428.22 as investors digested fresh security disclosures around the database maker’s software. The issue matters now because it affects core infrastructure. “MongoBleed” is tied to CVE-2025-14847 — a standard vulnerability identifier — and involves an “unauthenticated” attack path, meaning an attacker may not need a username or password to try to pull sensitive data from a vulnerable server. The U.S. National Vulnerability Database said the flaw was added on Dec. 29
Synopsys stock slips today as SNPS faces lawsuit deadline in thin year-end trade

Synopsys stock slips today as SNPS faces lawsuit deadline in thin year-end trade

NEW YORK, December 30, 2025, 15:44 ET — Regular session Synopsys shares were down $3.06, or 0.6%, at $475.91 in late-afternoon trade, after moving between $472.05 and $483.14 on the day. The chip-design software company sells electronic design automation tools — software used to design and verify semiconductors — and its stock has been sensitive to shifts in AI-linked tech sentiment into year-end. That sensitivity is getting tested on a holiday-thinned session when small headlines can drive outsized moves. “It’s just a healthy rebalancing of allocations more so than an emotionally driven sell-off,” said Mark Hackett, chief market strategist at
S&P Global (SPGI) stock slips near $529 as Fed minutes, year-end flows keep Wall Street muted

S&P Global (SPGI) stock slips near $529 as Fed minutes, year-end flows keep Wall Street muted

NEW YORK, December 30, 2025, 15:35 ET — Regular session S&P Global Inc shares edged lower on Tuesday as investors weighed a cautious year-end tape and fresh U.S. auto demand projections from the company’s Mobility unit. The stock was down 0.16% at $529.25 in afternoon trading, after moving between $528.24 and $531.97. S&P Global, a key supplier of financial data and benchmarks, operates across credit ratings, market intelligence, commodity data, automotive analytics and index services. That mix leaves the stock closely tied to shifts in capital-markets activity and risk appetite, from corporate bond issuance that drives ratings fees to assets
Why Qualys stock is sliding today: QLYS lags cybersecurity peers in late-year trade

Why Qualys stock is sliding today: QLYS lags cybersecurity peers in late-year trade

NEW YORK, December 30, 2025, 15:41 ET — Regular session Qualys Inc shares fell 2.5% to $133.93 in afternoon trading on Tuesday, after dropping as much as 4.2% earlier in the session. The stock closed at $137.34 on Monday. The decline landed as U.S. equities stayed range-bound in holiday-thin conditions, with technology and financial shares among the drags. “It’s just a healthy rebalancing of allocations more so than an emotionally driven sell-off,” said Mark Hackett, chief market strategist at Nationwide. Reuters That matters for Qualys because lighter year-end liquidity can exaggerate moves in single names, especially in software stocks where
Terns Pharmaceuticals stock slides today, testing the $40 level after December share sale

Terns Pharmaceuticals stock slides today, testing the $40 level after December share sale

NEW YORK, December 30, 2025, 15:30 ET — Regular session. Shares of Terns Pharmaceuticals, Inc. fell 2.8% to $40.34 in afternoon trading on Tuesday, after swinging between $39.99 and $41.98. The pullback puts the stock back around $40, the price used in the company’s recent upsized equity offering — a level traders often watch after a big deal resets supply and demand. That matters now because Terns’ December financing and trial update put new attention on how quickly the biotech can turn early leukemia data into larger studies, while also giving it a much longer cash runway. Biotech shares were
American Express stock dips today as Fed minutes weigh on financials; AXP earnings date in focus

American Express stock dips today as Fed minutes weigh on financials; AXP earnings date in focus

NEW YORK, December 30, 2025, 15:31 ET — Regular session Key points: American Express Co (AXP) shares fell 0.3% to $374.12 in late afternoon trading on Tuesday, after moving between $373 and $377 in the session. Visa and Mastercard were also down about 0.2% and 0.1%, respectively. The move matters because American Express is one of the higher-priced components of the Dow, a price-weighted index that gives bigger sway to costlier stocks. With year-end liquidity thin, small swings can ripple through benchmarks and sector ETFs more quickly. Investors are also treating AXP as a read-through on rate expectations and consumer
SRRK stock drops 3% today: What’s driving Scholar Rock shares as FDA reinspection nears

SRRK stock drops 3% today: What’s driving Scholar Rock shares as FDA reinspection nears

NEW YORK, December 30, 2025, 15:25 ET — Regular session Scholar Rock Holding Corp (SRRK) slid 3.2% to $43.76 in afternoon trading on Tuesday after opening at $45.18. The stock traded between $45.95 and $43.74. The move matters because Scholar Rock’s near-term valuation still hinges on regulatory timing for apitegromab, its lead drug candidate. he company said in an October update that the FDA classified a third-party manufacturing site in Bloomington, Indiana (formerly Catalent Indiana LLC, now fully owned and operated by Novo Nordisk) as “official action indicated” and that it requested a Type A meeting to discuss resubmitting its
Progressive stock ticks higher today after SEC filing flags 87,755-share gift; what investors watch next

Progressive stock ticks higher today after SEC filing flags 87,755-share gift; what investors watch next

NEW YORK, December 30, 2025, 15:29 ET — Regular session Shares of The Progressive Corporation (NYSE:PGR) were up about 0.7% at $230 on Tuesday afternoon after a regulatory filing disclosed a large gift of stock by a company director. The stock traded between $227.53 and $230.03, with about 1.0 million shares changing hands. The disclosure lands in a year-end market where liquidity is thin and small shifts in positioning can show up quickly in defensive financials such as insurers. Progressive is also heading into a key stretch for the personal auto insurance group, where investors tend to focus on whether

Stock Market Today

Vodafone shares steady up after Q3 wobble — Germany, buyback and next results now set the tone

Vodafone shares steady up after Q3 wobble — Germany, buyback and next results now set the tone

7 February 2026
Vodafone shares rose 1.47% to 110.60p Friday, recovering part of Thursday’s 4.68% drop after a Q3 update. Group revenue climbed 6.5% to €10.5 billion, but Germany’s 0.7% service revenue growth missed some forecasts. Vodafone launched a new €500 million buyback tranche, bringing total buybacks since May to €3.5 billion. Investors remain focused on Germany’s pace and cash flow execution.
NatWest Group stock: buyback filing and Rightmove mortgage deal set up a busy week

NatWest Group stock: buyback filing and Rightmove mortgage deal set up a busy week

7 February 2026
NatWest shares closed up 1.45% at 659.4 pence Friday, buoyed by a buyback of 797,428 shares and a new digital mortgage deal with Rightmove. The Bank of England held rates at 3.75% but signaled possible cuts, with markets pricing in two reductions for 2026. NatWest plans to expand its Accelerator community to 50,000 members by 2026. Annual results are due Feb. 13.
Unilever share price holds at 5,250p as results week looms — what investors watch next

Unilever share price holds at 5,250p as results week looms — what investors watch next

7 February 2026
Unilever shares closed flat at 5,250p in London Friday, underperforming the FTSE 100’s 0.6% gain. The company issued 4.2 million new shares for employee plans, bringing total shares to over 2.18 billion. Investors await Q4 and full-year results on Feb. 12, with analyst consensus pointing to 3.9% Q4 sales growth. Unilever’s U.S. ADR rose 0.8% to $72.12.
BP share price near 52-week high ahead of Feb 10 earnings as buyback runs on

BP share price near 52-week high ahead of Feb 10 earnings as buyback runs on

7 February 2026
BP shares closed up 1.9% at 478 pence Friday, just below a 52-week high, as the company continued buybacks ahead of next week’s results. BP repurchased 2.789 million shares on February 6. Oil prices firmed on geopolitical risk, with Brent at $68.05 a barrel, but sector outlook remains uncertain. Investors await BP’s earnings and dividend decision due Tuesday.
Go toTop